Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

Completed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

The purpose of the study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.

Key facts

Study ID

NCT01602393

Run by

Chiesi Farmaceutici S.p.A.

People needed

51

Starts

2012-05-01

Expected to finish

2013-10-01

Last updated by the study team

2014-02-06

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.
• Mini-Mental State Examination score higher than 24 at screening.
• MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.

You may not qualify if…

• Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
• Any medical condition that could explain the patients cognitive deficits.
• CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance
• MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter ≤ 10 mm).
• Geriatric Depression Scale (30-point scale) score > 9 at screening.
• History of stroke.
• Modified Hachinski ischemic scale score > 4 at screening.
• Women of childbearing potential.
• Vitamin B12 or folate deficiency.
• Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
• Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
• Concomitant use of donepezil at doses > 5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
• Concomitant use of memantine at dose > 20 mg/day.
• Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).

Where it is running

• Memory Enhancement Center of America, Inc. — Eatontown, New Jersey, United States
• Memory Center of New Jersey, Inc. — Monroe Twp, New Jersey, United States
• Memory Enhancement Center of NJ, Inc. — Toms River, New Jersey, United States
• Senior Adults Specialty Research — Austin, Texas, United States
• Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.